Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

That’s because it’s gradually dawning on investors that they no longer can count on lower interest rates and inflation to support higher stock and bond prices. They are realizing that ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

Getty Images Capital stock and treasury stock both describe two different types of a company's shares. Capital stock is the total amount of outstanding shares a company is authorized to issue ...

Revenue surged through 2023 and 2024, and the stock has soared as well; in November 2024, it was briefly the most valuable company in the world. Its chips are popular for running demanding ...

Stock market crash: Indian stocks came under significant selling pressure in Friday's trading session, January 17, driven by a sharp sell-off in banking and IT counters, which caused the frontline ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.